wrong .
As global justice campaigners demanded more transparency from Oxford and AstraZeneca over details of the deal to
supply doses to people in the developing world, the partnership confirmed in a statement that lower-income countries would receive the vaccine on a not-for-profit basis.
“A key element of Oxford’s partnership with AstraZeneca is the joint commitment to provide the vaccine
on a not-for-profit basis for the duration of the pandemic across the world, and in perpetuity to low- and middle-income countries,” it said.
Under the arrangement the Serum Institute of India (SSI) will produce 1bn doses under licence from AstraZeneca for India and low-income countries with the aim of producing 400m doses by the end of the year.
Jab that is part of global initiative to distribute doses will remain at low price ‘in perpetuity’
www.theguardian.com